Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 198.00K | Gross Profit |
-67.00K | -82.00K | -1.06M | -869.00K | -638.00K | 185.31K | EBIT |
-25.56M | -17.54M | -41.33M | -77.28M | -30.32M | -24.89M | EBITDA |
-9.26M | -20.16M | -39.46M | -76.64M | -31.80M | -25.87M | Net Income Common Stockholders |
-9.71M | -20.29M | -39.21M | -67.64M | -30.28M | -29.86M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
24.17M | 4.32M | 6.17M | 22.35M | 16.93M | 22.58M | Total Assets |
29.51M | 32.41M | 37.95M | 74.79M | 112.89M | 118.97M | Total Debt |
12.10M | 16.83M | 2.28M | 2.89M | 3.78M | 6.31M | Net Debt |
-12.08M | 12.51M | -3.89M | -19.45M | -13.15M | -16.27M | Total Liabilities |
16.77M | 29.02M | 27.94M | 32.91M | 43.33M | 44.04M | Stockholders Equity |
12.74M | 3.39M | 10.01M | 41.88M | 69.55M | 74.94M |
Cash Flow | Free Cash Flow | ||||
-15.30M | -13.45M | -19.46M | -23.94M | -25.61M | -24.85M | Operating Cash Flow |
-15.28M | -13.44M | -19.45M | -23.66M | -25.32M | -24.66M | Investing Cash Flow |
-12.00K | -15.00K | 197.00K | -279.00K | -291.00K | 13.80M | Financing Cash Flow |
10.09M | 11.60M | 3.08M | 29.36M | 19.96M | 21.77M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $5.32B | 3.32 | -40.25% | 2.90% | 17.93% | 2.14% | |
51 Neutral | $4.21M | ― | -111.83% | ― | 80.00% | 86.70% | |
43 Neutral | $4.16M | ― | -50.12% | ― | -1.56% | 5.01% | |
41 Neutral | $3.93M | ― | -87.31% | ― | ― | 6.87% | |
38 Underperform | $4.17M | ― | -285.35% | ― | 674.14% | 89.05% | |
29 Underperform | $4.17M | ― | -714.95% | ― | -100.00% | 76.55% | |
18 Underperform | $931.00K | ― | -21.57% | ― | ― | 97.84% |
Windtree Therapeutics, Inc. announced a 1-for-50 reverse stock split of its common stock, effective February 20, 2025, with the aim of meeting Nasdaq’s $1.00 minimum bid price requirement. This strategic move, approved by stockholders on February 3, 2025, is expected to consolidate shares and increase the stock price, impacting the company’s trading on the Nasdaq Capital Market.